IMMUNOVANT INC IMVT 深 沪
等待开盘 12-16 09:30:00 美东时间
26.00
-0.420
-1.59%
华盛通- 最 高27.2899
- 今 开26.73
- 成交量 358.31万股
- 最 低 25.565
- 昨 收 26.42
- 总市值 44.46亿
- 52周最高 27.2899
- 市盈率 静 --
- 换手率 2.10%
- 52周最低 12.72
- 委 比 94.59%
- 总股本 1.71亿
- 历史最高 53.75
- 量 比 1.30
- 振 幅 6.53%
- 历史最低 3.145
- 每 手 1
- 风险率 3.63%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
今天 09:36
Platform Technologies Drive $211B Surge in Precision Cancer Treatment
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 11, 2025 /PRNewswire/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift to...
12-11 23:17
Roivant Says Three New Drugs Could Hit the Market in the Next Three Years, Speeds Up Trial Timelines as It Prepares for Major Product Launches ,
Roivant (NASDAQ:ROIV) today is hosting an Investor Day in New York City. Roivant leadership will highlight key pipeline updates and provide an update on the Company's strategy for long-term value creation."We are at
12-11 20:35
Immunovant drops 7%, prices $550M stock offering
Clinical-stage immunology company Immunovant (IMVT) priced an underwritten offering of its common stock, with anticipated gross proceeds to Immunovant of ~$550M. Roivant Sciences, the company’s contro...
12-11 18:48
Immunovant Announces Pricing of $550 Million Common Stock Financing
Immunovant, a clinical-stage immunology company, announced the pricing of an underwritten offering of its common stock, expecting gross proceeds of approximately $550 million. The funds are intended to support its operations and capital expenditures through the potential commercial launch of IMVT-1402 for Graves' Disease. Immunovant is offering 26.2 million shares at $21.00 per share, with the offering expected to close on December 12, 2025. Leer...
12-11 06:29
Immunovant shares are trading higher. The company reported Q2 EPS results.
Immunovant shares are trading higher. The company reported Q2 EPS results.
11-10 22:09
Immunovant Q2 EPS $(0.73) Misses $(0.72) Estimate
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.72) by 0.69 percent. This is a 1.35 percent increase over losses of $(0.74) per share from the
11-10 20:03
Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining ar...
11-10 19:18
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
11-10 19:12
Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
Immunovant announced it will report its Q2 2025 financial results and provide a business update on November 10, 2025, at 8:00 a.m. ET. Interested parties can register for the Roivant conference call via the provided link. The presentation and webcast will also be accessible on Immunovant’s website, with an archived version available post-call. Immunovant is a clinical-stage immunology company focused on developing innovative therapies for autoimm...
10-27 20:10
